Edwards Lifesciences (NYSE: EW) announces investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement to acquire JenaValve Technology, a pioneer in the transcatheter treatment of aortic regurgitation (AR), a deadly disease that impacts a significant and growing population and is largely untreated today. Building on an investment made in 2016, Edwards has exercised its option to acquire Endotronix, a leader in heart failure (HF) management solutions.
Read the full article: Edwards Lifesciences Expands Structural Heart Portfolio with Acquisitions of JenaValve and Endotronix //
Source: https://www.businesswire.com/news/home/20240724177261/en/Edwards-Lifesciences-Expands-Structural-Heart-Portfolio-With-Acquisitions-of-JenaValve-and-Endotronix